Ovid Therapeutics (OVID) Corporate presentation summary

Strategic focus and innovation

• Developing small molecule medicines targeting neural hyperexcitability, focusing on GABA-AT and KCC2 as fundamental biological nodes with strong genetic and pharmacologic evidence for disease relevance.

• Emphasizing differentiated mechanisms of action and rational medicinal chemistry to create best-in-class or first-in-class neurotherapeutics.

• Aiming for a fully integrated neurotherapeutics company with sequential clinical and regulatory milestones through 2026-2027.

OV329 program highlights

• OV329 is a next-generation GABA-aminotransferase inhibitor with precision inhibition for drug-resistant epilepsies, pain, and neurodevelopmental disorders.

• Demonstrates validated mechanism, differentiated safety, and potential best-in-class therapeutic index compared to first-generation Sabril (vigabatrin).

• Multiple formulations available, including adult capsule, intravenous, and pediatric weight-based options.

• Clinical data show established safety, tolerability, and cortical inhibition, with Phase 2 studies underway.

• Intellectual property protection extends through 2041, with 10 additional patent families.

Market opportunity and unmet need

• Significant unmet need in treatment-resistant focal onset seizures (FOS), tuberous sclerosis complex (TSC), and infantile spasms (IS), with a combined addressable population exceeding 1.2 million in the US.

• OV329 targets a >$1 billion opportunity in FOS and $700M-$1 billion in TSC, with high market penetration potential and orphan pricing strategies.

• Unique mechanism and favorable safety profile position OV329 for first-line and long-duration use.